These participants had systolic and diastolic blood-pressure reductions of 28 to 54 mm Hg and 24 to 46 mm Hg, respectively. The study did not definitively delineate the risk in premenopausal women who take flibanserin at bedtime because 23 of the 25 participants were men, flibanserin was administered in the morning, and alcohol was consumed rapidly (within 10 minutes). In the phase 3 trials, in which alcohol consumption was not restricted and flibanserin was taken at bedtime, the incidence of syncope was 0.4% with flibanserin and 0.2% with placebo. Although these data appear more reassuring, the extent of alcohol use during these trials was not recorded. Because of residual concerns about the benefit–risk profile, the FDA rejected flibanserin again and requested additional data, including a study to ensure that CNS depression would not affect next-day driving performance. This rejection prompted allegations of gender bias at the FDA, based on erroneous claims that it had approved more than 20 drugs for male sexual dysfunction and none for women.
What should I do in case of OVERDOSE?
What should I tell my healthcare provider before using Addyi?
(Those making such assertions included Even the Score, an advocacy campaign partly funded by Sprout Pharmaceuticals, flibanserin's sponsor after Boehringer Ingelheim sold the rights to the drug.) The FDA rejected these claims and clarified what products had been approved (see Table 2). After completing the additional studies, Sprout submitted flibanserin for a third review. The FDA convened another advisory committee to obtain advice on the benefit–risk profile, given the new data. By a vote of 18 to 6, the committee recommended approval, though some members said it was a difficult decision.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Original | 100mg | 64 + 4 Pills | 264.15€ 251.57€ | |
| Cialis Generic | 2.5mg | 20 Pills | 40.73€ 38.79€ | |
| Viagra Generic | 50mg | 60 + 4 Pills | 83.93€ 79.93€ | |
| Cialis Generic | 10mg | 10 Pills | 31.41€ 29.91€ | |
| Levitra Generic | 10mg | 360 + 10 Pills | 407.94€ 388.51€ | |
| Kamagra Polo | 100mg | 60 + 4 Pills | 189.39€ 180.37€ | |
| Cialis Generic | 60mg | 180 + 10 Pills | 313.11€ 298.20€ | |
| Cialis Soft Tabs | 20mg | 90 + 6 Pills | 216.71€ 206.39€ | |
| Viagra Soft Tabs | 100mg | 10 Pills | 36.93€ 35.17€ | |
| Kamagra Oral Jelly | 100 mg | 10 Sachets | 54.55€ 51.95€ | |
| Cialis Black | 80mg | 120 + 8 Pills | 264.77€ 252.16€ | |
| Kamagra Effervescent Tablets | 100 mg | 42 + 7 Pills | 122.97€ 117.11€ | |
| Cialis Original | 20mg | 22 + 2 Pills | 129.20€ 123.05€ | |
| Cialis Generic | 10mg | 20 Pills | 48.23€ 45.93€ | |
| Cialis Generic | 40mg | 60 + 6 Pills | 130.98€ 124.74€ | |
| Viagra Generic | 25mg | 90 + 6 Pills | 105.03€ 100.03€ |
In general, those recommending approval acknowledged the small treatment effects and substantial safety concerns but considered the unmet medical need. All votes for approval were contingent on the inclusion of risk-mitigation strategies beyond labeling. After the advisory committee meeting, the FDA received requests to reject flibanserin again, citing insufficient alcohol-interaction data in women, the infeasibility of abstaining indefinitely from alcohol, drug–drug interactions, the importance of nonpharmacologic approaches to HSDD, concerns about “medicalizing” low sexual desire, and the change from HSDD to “female sexual interest/arousal disorder” (FSIAD) in the newest edition of the Diagnostic and Statistical Manual of Mental Disorders. Patients with HSDD generally meet the criteria for FSIAD if they've had symptoms for at least 6 months and are typically unreceptive to a partner's attempts to initiate sexual activity, but whereas HSDD requires distress caused by low sexual desire, the definition of FSIAD includes distress caused by low sexual desire, low sexual arousal, or both.
Problems and controversies
It's impossible to know any drug's full safety profile at the time cenforce 100mg tablet of approval. Beyond the safety measures noted above, the FDA is requiring three postapproval trials to further elucidate the alcohol interaction in women, plus enhanced pharmacovigilance for hypotension, syncope, accidental injury, and death. The agency will be able to take regulatory action as needed on the basis of the resulting data. We believe this is a reasonable approach that balances safety and access. Although the FDA does not regulate off-label use, we encourage responsible prescribing and emphasize that the approval is only for the population that was studied — premenopausal women with HSDD.
Hazard Classifications
This article was published on December 9, 2015, at NEJM.org. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Patient-focused drug development public meeting and scientific workshop on female sexual dysfunction, 2014 ( Transcript for the June 18, 2010, meeting of the Advisory Committee for Reproductive Health Drugs ( Nguyen, CP, Hirsch, MS, Moeny, D, Kaul, S, Mohamoud, M, Joffe, HV. Testosterone and “age-related hypogonadism” -- FDA concerns. N Engl J Med 2015;373:689-691 Results from the 2013 National Survey on Drug Use and Health: summary of national findings. The clinical trials, and therefore the FDA, evaluated flibanserin only for treatment of HSDD. After careful libido booster for woman consideration, the FDA followed the second advisory committee's recommendations, concluding that efficacy had been established; although the average treatment effects were small, about 10% more flibanserin-treated patients than placebo-treated patients reported clinically meaningful improvement.
- Flibanserin is classified as a centrally acting serotonergic agent.
- It is not a testosterone-based therapy, unlike some other treatments.
- The FDA approval was based on studies showing increased sexual desire in women.
- The medication can cause sleep disturbances, including somnolence.
- Flibanserin has a potential for drug interactions with CYP3A4 inhibitors.
- It is recommended to start treatment at least 4 weeks before expecting improvement.
- Discontinuation of the drug normally leads to the loss of effects.
- The drug's efficacy is modest compared to some male sexual dysfunction drugs.
- Initiation of therapy involves screening for contraindications.
Assuming that the effects of the alcohol interaction in women are at least as severe as those observed in men, the FDA required a boxed warning and an alcohol contraindication.
if she’s saying these things, it may be hsdd
Rockville, MD: Substance Abuse and Mental Health Administration, 2014 ( Addyi tablets (FDA staff reviews, REMS, labels and action letters). Any commercial reuse of NEJM Group content requires permission. Published ahead of print: December 9, 2015 From the Food and Drug Administration, Silver Spring, MD. Select the format you want to export the citation of this publication. Management of sexual dysfunction in menopause: an update on evidence-based strategies, Expert Review of Endocrinology & Metabolism, 21, 1, (13-27), (2025).
FDA-approved indications
Impact of Hypoactive Sexual Desire Disorders on Mental Well-Being and Daily Activities: Pharmacological Therapy?, Hypoactive Sexual Desire Disorder, (55-63), (2025). Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies, Expert Review gel erectile dysfunction of Clinical Pharmacology, 18, 10, (739-751), (2025). Genitourinary Symptoms of Menopause in Patients with Serious Illness #511, Journal of Palliative Medicine, 28, 10, (1409-1411), (2025). Single-nucleus RNA sequencing reveals cellular and molecular signatures in the prefrontal cortex of a hypoactive sexual desire disorder rat model, The Journal of Sexual Medicine, 22, 11, (1911-1922), (2025). Advancing Women’s Health: A Scoping Review of Pharmaceutical Therapies for Female Sexual Dysfunction, Sexes, 6, 3, (38), (2025). In addition, taking into account the widespread use of alcohol in the United States,4 the agency required a risk evaluation and mitigation strategy (REMS) with “elements to assure safe use” to ensure that the benefits outweigh the increased risk of hypotension and syncope with alcohol.
Real Science. Real Results.
As with other medications that have dangerous drug interactions, that risk will also be managed with labeling, including a boxed warning and a contraindication for moderate and strong CYP3A4 inhibitors, and by using existing software to screen for drug–drug interactions before flibanserin is dispensed. Not all members of the review team recommended the same regulatory action for flibanserin. Some concluded that its benefit–risk profile was unfavorable, even with the safety measures described here, and recommended against approval.5 In their view, the observed treatment effects were offset by the potentially life-threatening hypotension, syncope, accidental injuries related to CNS depression, and the unclear clinical significance of a drug-related increase in malignant mammary tumors in female mice. They also questioned the generalizability of the phase 3 safety data to all premenopausal women likely to use flibanserin, given the trials' extensive exclusion criteria. At a minimum, they recommended a preapproval alcohol-interaction study in women.
Contact Us
Transparent, robust scientific discussions among FDA staff are encouraged, so that all internal viewpoints can be considered before decisions are finalized. The FDA also considered the recommendations from advisory committee members and the public, including letters both favoring and opposing approval. The agency's approach aims to ensure that patients and prescribers know about the risks so they can make informed decisions about using flibanserin. Because HSDD is symptomatic, patients can directly assess whether any improvements they experience are worth the risks. Flibanserin should be discontinued if HSDD symptoms do not improve after 8 weeks of treatment. This requirement means that only certified prescribers and pharmacies that have enrolled in the REMS program and completed training can prescribe or dispense flibanserin; prescribers must counsel patients to abstain from alcohol, using a patient–provider agreement form that both parties sign; and certified pharmacies must dispense flibanserin only to patients with a prescription from a certified prescriber and must counsel the patient to abstain from alcohol before dispensing each prescription. As with other medications that can cause CNS depression, that risk will be managed with labeling, including a warning and a medication guide instructing patients to take flibanserin at bedtime and not to engage in activities requiring full alertness, such as driving, until at least 6 hours after taking the drug and until they know how they're affected by it. As with other medications that have dangerous drug interactions, that risk will also be managed with labeling, including a boxed warning and a contraindication for moderate and strong CYP3A4 inhibitors, and by using existing software to screen for drug–drug interactions before flibanserin is dispensed. Not all members of the review team recommended the same regulatory action for flibanserin. Some concluded that its benefit–risk profile was unfavorable, even with the safety measures described here, and recommended against approval.5 In their view, the observed treatment effects were offset by the potentially life-threatening hypotension, syncope, accidental injuries related to CNS depression, and the unclear clinical significance of a drug-related increase in malignant mammary tumors in female mice. They also questioned the generalizability of the phase 3 safety data to all premenopausal women likely to use flibanserin, given the trials' extensive exclusion criteria. At a minimum, they recommended a preapproval alcohol-interaction study in women. Transparent, robust scientific discussions among FDA staff are encouraged, so that all internal viewpoints can be considered before decisions are finalized.
IN THEIR WORDS
In general, those recommending approval acknowledged the small treatment effects and substantial safety concerns but considered the unmet medical need. All votes for approval were contingent on the inclusion of risk-mitigation strategies beyond labeling. After the advisory committee meeting, the FDA received requests to reject flibanserin again, citing insufficient alcohol-interaction data in women, the infeasibility of abstaining indefinitely from alcohol, drug–drug interactions, the importance of nonpharmacologic approaches to HSDD, concerns about “medicalizing” low sexual desire, and the change from HSDD to “female sexual interest/arousal disorder” (FSIAD) in the newest edition of the Diagnostic and Statistical Manual of Mental Disorders. Patients with HSDD generally meet the criteria for FSIAD if they've had symptoms for at least 6 months and are typically unreceptive to a partner's attempts to initiate sexual activity, but whereas HSDD requires distress caused by low sexual desire, the definition of FSIAD includes distress caused by low sexual desire, low sexual arousal, or both. The clinical trials, and therefore the FDA, evaluated flibanserin only for treatment of HSDD.
Interactions with Food/Tobacco/Alcohol
After careful libido booster for woman consideration, the FDA followed the second advisory committee's recommendations, concluding that efficacy had been established; although the average treatment effects were small, about 10% more flibanserin-treated patients than placebo-treated patients reported clinically meaningful improvement. Assuming that the effects of the alcohol interaction in women are at least as severe as those observed in men, the FDA required a boxed warning and an alcohol contraindication. In addition, taking into account the widespread use of alcohol in the United States,4 the agency required a risk evaluation and mitigation strategy (REMS) with “elements to assure safe use” to ensure that the benefits outweigh the increased risk of hypotension and syncope with alcohol. This requirement means that only certified prescribers and pharmacies that have enrolled in the REMS program and completed training can prescribe or dispense flibanserin; prescribers must counsel patients to abstain from alcohol, using a patient–provider agreement form that both parties sign; and certified pharmacies must dispense flibanserin only to patients with a prescription from a certified prescriber and must counsel the patient to abstain from alcohol before dispensing each prescription. As with other medications that can cause CNS depression, that risk will be managed with labeling, including a warning and a medication guide instructing patients to take flibanserin at bedtime and not to engage in activities requiring full alertness, such as driving, until at least 6 hours after taking the drug and until they know how they're affected by it. The FDA also considered the recommendations from advisory committee members and the public, including letters both favoring and opposing approval. The agency's approach aims to ensure that patients and prescribers know about the risks so they can make informed decisions about using flibanserin.
| Point | Explanation |
|---|---|
| Take at bedtime | To reduce dizziness and fatigue |
| Avoid alcohol | Increases risk of hypotension and sedation |
| Report side effects early | Especially severe dizziness, fainting, or allergic reactions |
Because HSDD is symptomatic, patients can directly assess whether any improvements they experience are worth the risks. Flibanserin should be discontinued if HSDD symptoms do not improve after 8 weeks of treatment.
| Condition | Reason |
|---|---|
| Alcohol Use | Increased sedation & hypotension |
| CYP3A4 Inhibitors | Elevated flibanserin levels |
| Liver impairment | Reduced metabolism & clearance |
| Hypotension | Risk of further blood pressure drop |
It's impossible to know any drug's full safety profile at the time cenforce 100mg tablet of approval. Beyond the safety measures noted above, the FDA is requiring three postapproval trials to further elucidate the alcohol interaction in women, plus enhanced pharmacovigilance for hypotension, syncope, accidental injury, and death.
| Parameter | Description | Typical Values |
|---|---|---|
| Absorption | Rapid, high bioavailability | ~52% |
| Peak Plasma Levels | 1-2 hours after dosing | ~1.5 hours |
| Half-life | Duration of effect | 11 hours |
| Metabolism | Hepatic via CYP3A4 | Major route |
| Excretion | Mainly via urine | 87% in urine |
The agency will be able to take regulatory action as needed on the basis of the resulting data. We believe this is a reasonable approach that balances safety and access. Although the FDA does not regulate off-label use, we encourage responsible prescribing and emphasize that the approval is only for the population that was studied — premenopausal women with HSDD. This article was published on December 9, 2015, at NEJM.org.
- Flibanserin acts as an agonist on dopamine receptors and antagonist on certain serotonin receptors.
- The medication can take several weeks to show benefits.
- It is not approved for use in postmenopausal women.
- Flibanserin was initially developed as an antidepressant.
- It has a pharmacokinetic profile with a half-life of around 13 hours.
- Dose adjustments are necessary for patients with liver impairment.
- The drug can cause hypotension, especially with alcohol or CYP3A4 inhibitors.
- Patients are monitored for side effects such as sleepiness and low blood pressure.
- Flibanserin's efficacy is moderate and varies among women.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Patient-focused drug development public meeting and scientific workshop on female sexual dysfunction, 2014 ( Transcript for the June 18, 2010, meeting of the Advisory Committee for Reproductive Health Drugs ( Nguyen, CP, Hirsch, MS, Moeny, D, Kaul, S, Mohamoud, M, Joffe, HV. Testosterone and “age-related hypogonadism” -- FDA concerns. N Engl J Med 2015;373:689-691 Results from the 2013 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: Substance Abuse and Mental Health Administration, 2014 ( Addyi tablets (FDA staff reviews, REMS, labels and action letters).
How much does Addyi (flibanserin) cost?
These participants had systolic and diastolic blood-pressure reductions of 28 to 54 mm Hg and 24 to 46 mm Hg, respectively. The study did not definitively delineate the risk in premenopausal women who take flibanserin at bedtime because 23 of the 25 participants were men, flibanserin was administered in the morning, and alcohol was consumed rapidly (within 10 minutes). In the phase 3 trials, in which alcohol consumption was not restricted and flibanserin was taken at bedtime, the incidence of syncope was 0.4% with flibanserin and 0.2% with placebo. Although these data appear more reassuring, the extent of alcohol use during these trials was not recorded. Because of residual concerns about the benefit–risk profile, the FDA rejected flibanserin again and requested additional data, including a study to ensure that CNS depression would not affect next-day driving performance.
Dosage Forms & Strengths
This rejection prompted allegations of gender bias at the FDA, based on erroneous claims that it had approved more than 20 drugs for male sexual dysfunction and none for women. (Those making such assertions included Even the Score, an advocacy campaign partly funded by Sprout Pharmaceuticals, flibanserin's sponsor after Boehringer Ingelheim sold the rights to the drug.) The FDA rejected these claims and clarified what products had been approved (see Table 2). After completing the additional studies, Sprout submitted flibanserin for a third review. The FDA convened another advisory committee to obtain advice on the benefit–risk profile, given the new data. By a vote of 18 to 6, the committee recommended approval, though some members said it was a difficult decision. Any commercial reuse of NEJM Group content requires permission.
i have little to no sexual desire
Enhancing Sexual Health for Cancer Survivors, American Society of Clinical Oncology Educational Book, 45, 3, (2025). Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM), ESMO Open, 10, 6, (105311), (2025). Addressing Sexual Health in Breast Cancer Survivors: Evidence-Based Practices and Clinical Considerations, Current Treatment Options in Oncology, 26, 6, (476-485), (2025). Female Sexual Dysfunctions and Reproductive Psychiatry, Textbook of Women’s Reproductive Mental Health, (67-92), (2024). Generic name: flibanserin [ flib-AN-ser-in ] Brand name: Addyi Drug class: Miscellaneous central nervous system agents The use of flibanserin and alcohol together close in time increases the risk of severe hypotension and syncope.
Pregnancy Categories
Counsel patients to wait at least 2 hours after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip their bedtime flibanserin dose if they have consumed 3 or more standard alcoholic drinks that evening. Flibanserin is contraindicated with moderate or strong CYP3A4 inhibitors and in patients with hepatic impairment due to risk of severe hypotension and syncope . Published ahead of print: December 9, 2015 From the Food and Drug Administration, Silver Spring, MD. Select the format you want to export the citation of this publication. Management of sexual dysfunction in menopause: an update on evidence-based strategies, Expert Review of Endocrinology & Metabolism, 21, 1, (13-27), (2025). Impact of Hypoactive Sexual Desire Disorders on Mental Well-Being and Daily Activities: Pharmacological Therapy?, Hypoactive Sexual Desire Disorder, (55-63), (2025). Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies, Expert Review gel erectile dysfunction of Clinical Pharmacology, 18, 10, (739-751), (2025). Genitourinary Symptoms of Menopause in Patients with Serious Illness #511, Journal of Palliative Medicine, 28, 10, (1409-1411), (2025). Single-nucleus RNA sequencing reveals cellular and molecular signatures in the prefrontal cortex of a hypoactive sexual desire disorder rat model, The Journal of Sexual Medicine, 22, 11, (1911-1922), (2025). Advancing Women’s Health: A Scoping Review of Pharmaceutical Therapies for Female Sexual Dysfunction, Sexes, 6, 3, (38), (2025). Enhancing Sexual Health for Cancer Survivors, American Society of Clinical Oncology Educational Book, 45, 3, (2025). Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM), ESMO Open, 10, 6, (105311), (2025). Addressing Sexual Health in Breast Cancer Survivors: Evidence-Based Practices and Clinical Considerations, Current Treatment Options in Oncology, 26, 6, (476-485), (2025). Female Sexual Dysfunctions and Reproductive Psychiatry, Textbook of Women’s Reproductive Mental Health, (67-92), (2024). Generic name: flibanserin [ flib-AN-ser-in ] Brand name: Addyi Drug class: Miscellaneous central nervous system agents The use of flibanserin and alcohol together close in time increases the risk of severe hypotension and syncope. Counsel patients to wait at least 2 hours after consuming 1 or 2 standard alcoholic drinks before taking flibanserin at bedtime or to skip their bedtime flibanserin dose if they have consumed 3 or more standard alcoholic drinks that evening. Flibanserin is contraindicated with moderate or strong CYP3A4 inhibitors and in patients with hepatic impairment due to risk of severe hypotension and syncope .